Showing results (291-300 of 515) with videos related to

Sort By:
Pageof 52
Crohn'S & Colitis 360|February 13, 2023
Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel DiseaseJuan E Corral, Joshua Y Kwon, Freddy Caldera, et al.
Crohn'S & Colitis 360|February 13, 2023
Burden of Inflammatory Bowel Disease on Patient Mood, Fatigue, Work, and Health-Related Quality of Life in Thailand: A Case-Control StudyKasenee Tiankanon, Julajak Limsrivilai, Napapat Poocharoenwanich, et al.
Crohn'S & Colitis 360|February 13, 2023
The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn's Disease With Poor Prognostic Factors: The MODIFY StudyGerassimos J Mantzaris, Christos Zeglinas, Angeliki Theodoropoulou, et al.
Crohn'S & Colitis 360|February 13, 2023
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination ServicesNadeen Hussain, Deborah Proctor, Badr Al-Bawardy
Crohn'S & Colitis 360|February 13, 2023
A Systematic Review of Fecal Microbiota Transplant for the Management of PouchitisMaia Kayal, Thomas Lambin, Rachel Pinotti, et al.
Crohn'S & Colitis 360|February 13, 2023
Development and Validation of the IBD-REFER Criteria: Early Referral for Suspected Inflammatory Bowel Diseases in Adults and ChildrenOhad Atia, Adi Shosberger, Gili Focht, et al.
Crohn'S & Colitis 360|February 13, 2023
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov ModelingAkihito Uda, Yuki Eto, Yuxin Li, et al.
Crohn'S & Colitis 360|February 13, 2023
Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or VedolizumabMichael Chiorean, Anita Afzali, Raymond K Cross, et al.
Crohn'S & Colitis 360|February 13, 2023
A Missing Piece of the Puzzle: Patient and Provider Perspectives on Pain Management Needs and Opioid Prescribing in Inflammatory Bowel Disease CareSalva N Balbale, Cassandra B Iroz, Willemijn L A Schäfer, et al.
Crohn'S & Colitis 360|February 13, 2023
Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease PatientsMarieke J Pierik, Andrea E van der Meulen, Klaas Van der Linde, et al.
Pageof 52